September 25th, 2018
•To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.
Videos relacionados
Lung Tumor Cell Recruitment Assay
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
Analysis of Cancer Cell Invasion and Anti-metastatic Drug Screening Using Hydrogel Micro-chamber Array (HMCA)-based Plates
Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados